ArticleDermatology practical & conceptual2026
Intra-Individual Comparative Study of Methotrexate versus Triamcinolone Acetonide Delivered via Microneedling for Recalcitrant Alopecia Areata.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlopecia areata (AA) is a chronic, immune-mediated, non-scarring hair loss disorder. While intralesional corticosteroids remain first-line treatment, some patients with recalcitrant AA respond poorly. Microneedling enhances transdermal drug delivery via microchannel formation. Methotrexate, an established systemic immunomodulator, is effective in resistant AA but has been less extensively studied for topical administration.
objectivesTo compare the efficacy and safety of methotrexate and triamcinolone acetonide, both delivered via microneedling, in recalcitrant AA.
methodsIn this prospective, intra-individual comparative study, 34 patients with at least two patches of recalcitrant AA received microneedling followed by topical methotrexate (25 mg/mL) on one site and triamcinolone acetonide (5 mg/mL) on a matched site, administered fortnightly for 12 weeks. The primary outcome was the change in Severity of Alopecia Tool (SALT) score. Secondary outcomes included trichoscopic assessment, blinded photographic evaluation, patient satisfaction, and relapse rates at three-month follow-up. Safety was assessed at each visit.
resultsBoth treatment modalities were associated with overall clinical improvement. Methotrexate-treated areas showed significantly greater reductions in SALT scores (P<0.05), higher levels of patient satisfaction, and lower relapse rates at follow-up compared to triamcinolone-treated areas. Both modalities were well tolerated, with only mild, transient adverse effects reported.
conclusionsIn this pilot intra-individual study, microneedling-assisted methotrexate appeared to provide superior short-term clinical outcomes to triamcinolone acetonide with an acceptable safety profile in recalcitrant AA. These findings warrant confirmation in larger, adequately powered controlled trials with 6-12-month follow-up to evaluate durability, relapse, and long-term safety.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.